Tesamorelin (20 mg Vial) Dosage Protocol

Dosing & Reconstitution Overview

Tesamorelin (research code TH9507) is a stabilised analog of human growth-hormone-releasing hormone (GHRH) studied for its effect on visceral adipose tissue. The figures below are compiled strictly for laboratory and educational reference — they describe how the compound was handled and dosed across published trials, not a recommendation for use in humans or animals.

For a 20 mg vial, adding 3.0 mL of bacteriostatic water yields a concentration of approximately 6.67 mg/mL (≈6,667 mcg/mL). At that concentration, every 0.15 mL drawn on a U-100 insulin syringe equals 15 units and delivers about 1 mg of material, so a full 2 mg dose corresponds to roughly 0.30 mL or 30 units.

Standard (Gradual) Titration Schedule

The gradual schedule reflects the once-daily evening regimen used in the published HIV-associated lipodystrophy trials, opening at a reduced first-week amount before settling at the studied maintenance dose.

Reconstitution Steps

1. Let the sealed lyophilized vial and the bacteriostatic water reach room temperature, then wipe both stoppers with an alcohol swab.
2. Draw 3.0 mL of bacteriostatic water with a sterile syringe and inject it slowly down the inside wall of the vial — never directly onto the powder pellet — to limit foaming.
3. Swirl gently until fully dissolved. Do not shake; aggressive agitation can shear the peptide.
4. The solution should be clear and colourless. Label the vial with the concentration (~6.67 mg/mL) and the reconstitution date.
5. Refrigerate at 2–8 °C, protected from light, and draw subsequent volumes with a fresh sterile syringe each time. When reconstituted with bacteriostatic water, use within about 7 days.

Extended (Continuous) Schedule

Published trials carried the 2 mg daily dose well beyond the initial weeks, with continued visceral-fat benefit observed across longer evaluation windows. The table below summarises the studied maintenance and extended timepoints rather than a faster escalation.

Supplies Needed

• Tesamorelin vials (20 mg): ~6 vials for an 8-week run at 2 mg/day; ~9 vials for 12 weeks; ~11 vials for 16 weeks.
• Insulin syringes (U-100, 1 mL): ~56 for 8 weeks, ~84 for 12 weeks, ~112 for 16 weeks (one fresh syringe per daily draw).
• Bacteriostatic water (10 mL): ~2 bottles for 8 weeks, 3 for 12 weeks, 4 for 16 weeks.
• Alcohol swabs: two 100-count boxes for 8–12 weeks, three for a 16-week schedule.

Protocol Overview

• Research goal: model visceral-fat reduction via stimulated endogenous growth-hormone release.
• Schedule: once-daily subcutaneous administration, preferably in the evening, in the published model.
• Dose band: 1 mg run-in, then 2 mg daily maintenance.
• Fill: 20 mg lyophilized, reconstituted to ~6.67 mg/mL with 3 mL diluent.
• Storage: 2–8 °C dry and once reconstituted; use within ~7 days after mixing.

Dosing Protocol Notes

• Hold the first week at the 1 mg run-in level before moving to the 2 mg maintenance dose.
• Keep administration on a fixed daily cadence, evening preferred, for steady exposure modelling that follows the natural GH pulse.
• Continuity matters more than escalation here — the studied benefit accrued over months at a constant 2 mg.
• IGF-1 is the standard pharmacodynamic readout used to confirm activity in the trial protocols.

Storage Instructions

Keep sealed lyophilized vials at 2–8 °C, protected from light; some newer formulations are reported stable at 20–25 °C. Once reconstituted with bacteriostatic water, refrigerate at 2–8 °C and use within about 7 days. If sterile (preservative-free) water is used instead, the solution should be used immediately and any remainder discarded. Avoid repeated freeze-thaw cycles and let refrigerated solution warm slightly before drawing.

Important Handling Notes

• Use a sterile syringe for every draw and never re-enter the vial with a used needle.
• Inject diluent down the vial wall and swirl gently — foaming and shaking degrade the peptide.
• Track the 7-day post-reconstitution window and discard solution beyond it.
• Document each draw — date, volume, remaining material — for reproducibility.

How Tesamorelin Works

Tesamorelin is a synthetic analog of human GHRH (growth-hormone-releasing hormone) stabilised against enzymatic breakdown. It binds GHRH receptors on the anterior pituitary and prompts the gland to release growth hormone in a pulsatile pattern that mirrors natural physiology, which in turn raises circulating IGF-1. That signalling cascade drives lipolysis — favouring breakdown of visceral fat — along with protein synthesis and broader metabolic shifts. Because it stimulates the body's own GH output rather than supplying exogenous hormone, the response stays subject to normal feedback regulation.

Reported Benefits & Side Effects

Benefits observed in trials

• Meaningful reduction in visceral adipose tissue, typically measurable after about 3–6 months.
• Improved lipid profiles and signals of reduced liver fat in fatty-liver contexts.
• Exploratory cognitive-function findings in older adults (research ongoing).
• Benefit generally maintained during continuous use out to roughly 52 weeks.

Side effects reported

• Injection-site reactions — mild redness, itching, pain or bruising.
• Musculoskeletal complaints such as joint pain, muscle aches and peripheral edema.
• Occasional carpal-tunnel-type tingling or numbness in the extremities.
• IGF-1 elevation that warrants monitoring, plus small increases in HbA1c in some study populations.

Supporting Lifestyle Factors (Research Context)

• Protein-forward, micronutrient-dense nutrition consistent with the published study designs.
• Combined resistance and aerobic activity to support the metabolic response.
• Adequate sleep, since GH release is tied to circadian and sleep-driven pulses, plus standard hydration and stress controls.

Injection Technique (Reference Only)

• Clean the vial stopper and the skin with alcohol swabs and let them air-dry fully.
• Pinch a skinfold — the abdomen at least two inches from the navel is the usual reference site.
• Insert subcutaneously at 90° where there is adequate fat, or 45° in leaner tissue.
• Release the pinch, inject slowly, pause 2–3 seconds before withdrawing, rotate sites to avoid lipohypertrophy, and dispose of sharps in an approved container.

References

Related Protocols